Effects of arachidonic acid intake on inflammatory reactions in dextran sodium sulphate-induced colitis in rats

Yukiko Naito1,2*, Xu Ji1,3, Shigehiro Tachibana4, Satoko Aoki4, Mami Furuya4, Yoshiyuki Tazura4, Daisuke Miyazawa5, Akiko Harauma6, Toru Moriguchi6, Tomoko Nagata4, Naoharu Iwai1 and Naoki Ohara5

1Department of Genomic Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka 565-8565, Japan
2Department of Health Science, School of Allied Health Sciences and Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa 252-0373, Japan
3State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650201, China
4Hatano Research Institute, Food and Drug Safety Center, Hadano, Kanagawa 257-8523, Japan
5College of Pharmacy, Kinjo Gakuin University, Nagoya, Aichi 463-8521, Japan
6Department of Food and Life Science, School of Life and Environmental Science, Azabu University, Sagamihara, Kanagawa 252-0206, Japan

(Submitted 9 October 2014 – Final revision received 22 May 2015 – Accepted 29 May 2015 – First published online 3 August 2015)

Abstract

The aim of this study was to investigate the effects of the administration of oral arachidonic acid (AA) in rats with or without dextran sulphate sodium (DSS)-induced inflammatory bowel disease. Male Wistar rats were administered AA at 0, 5, 35 or 240 mg/kg daily by gavage for 8 weeks. Inflammatory bowel disease was induced by replacing drinking water with 3 % DSS solution during the last 7 d of the AA dosing period. These animals passed loose stools, diarrhoea and red-stained faeces. Cyclo-oxygenase-2 concentration and myeloperoxidase activity in the colonic tissue were significantly increased in the animals given AA at 240 mg/kg compared with the animals given AA at 0 mg/kg. Thromboxane B2 concentration in the medium of cultured colonic mucosae isolated from these groups was found to be dose-dependently increased by AA, and the increase was significant at 35 and 240 mg/kg. Leukotriene B4 concentration was also significantly increased and saturated at 5 mg/kg. In addition, AA at 240 mg/kg promoted DSS-induced colonic mucosal oedema with macrophage infiltration. In contrast, administration of AA for 8 weeks, even at 240 mg/kg, showed no effects on the normal rats. These results suggest that in rats with bowel disease AA metabolism is affected by oral AA, even at 5 mg/kg per d, and that excessive AA may aggravate inflammation, whereas AA shows no effects in rats without inflammatory bowel disease.

Key words: Arachidonic acid; Colitis; Dextran sodium sulphate; Supplementation

Arachidonic acid (AA, 20 : 4n-6) is one of the n-6 PUFA present in the cell membrane and is essential for maintaining cell functions. AA has been reported to play a crucial role in the brain functions of both aged animals and elderly people(1–6). Moreover, as AA is also essential for perinatal and neonatal development(7–9), AA is added to infant formula(10).

However, it should be noted that AA serves as a precursor to pro- and anti-inflammatory eicosanoids. Excessive AA consumption can occur as long as food supplements containing AA are available on the market and consumers include, inevitably, persons who are subject to inflammatory diseases, manifested or not. Thus, it is important to evaluate the influence of AA on an underlying inflammation. In this study, whether or not dextran sulphate sodium (DSS)-induced colitis was affected by AA intake was examined in rats. The reason DSS-induced colitis was chosen as the inflammation model was that the model is structurally and clinically similar to human ulcerative colitis(11,12) and has been used in previous studies dealing with AA effects on experimental inflammation(13,14).

In the present study, rats were orally administered AA at doses of 0, 5, 35 and 240 mg/kg per d for 8 weeks; 5 mg/kg per d corresponded approximately to the doses used in previous human studies(5,15), and the highest – 240 mg/kg per d – was set to examine the possible toxicity of AA. Thus, in parallel with the

Abbreviations: 6-keto PGF1α, 6-keto prostaglandin F1α; AA, arachidonic acid; COX-2, cyclo-oxygenase-2; DSS, dextran sulphate sodium; LTB4, leukotriene B4; MPO, myeloperoxidase; PGE2, prostaglandin E2; TXB2, thromboxane B2.

* Corresponding author: Dr Y. Naito, fax +81 42 778 8073, email naitoy@kitasato-u.ac.jp
rats with DSS-induced colitis, those without DSS-induced colitis were administered AA at 0 and 240 mg/kg per d for 8 weeks and were observed for toxicological signs.

Methods

Fatty acid analysis of arachidonic acid-rich dietary oil and vehicle oil

AA-rich dietary oil and the vehicle oil (n 3) were diluted with a methanol-hexane vehicle containing butylhydroxytoluene as an antioxidant and docosatrienoic acid methyl ester (C22 : 3 methyl ester) as an internal standard. After adding acetyl chloride, the mixture was heated at 100°C for 60 min for extraction and methylation of lipids. The samples were shaken with potassium carbonate solution. Fatty acid methyl esters in the hexane layer were determined using Agilent 7890A gas chromatograph (Agilent Technologies) with a split injector (Agilent 7693 automatic liquid sampler; Agilent Technologies), and were detected using a flame ionisation detector (Agilent Technologies). The GC column used was a DB-FFAP 15 m × 0.10 mm i.d. with 0·10 μm film thickness (J&W Scientific from Agilent Technologies). The oven temperature programme was initiated at 150°C with a 0·25-min hold, and then ramped up at 35°C/min to 200°C, then at 8°C/min to 225°C with a 3·2-min hold and finally ramped up at 80°C/min to 248°C with a 14·7-min hold. The detector and injector temperatures were both set at 250°C.

Animals, dosage of arachidonic acid and dextran sulphate sodium treatment

Male Wistar rats (Japan SLC), 4 weeks old, were acclimatised for 1 week and housed individually in metal cages with mesh bottoms. The temperature and humidity of the breeding room were maintained at 21–25°C and 40–75·0 %, respectively, with ventilation at 15 changes/h and a 12·h light/dark cycle. The rats were allowed free access to a standard diet for rodents (CE-2; CLEA Japan) and tap water.

AA-rich dietary oil (2·40 % (w/w) AA; Cabio Bioengineering) was mixed with vehicle oil, a mixture of lard: rapeseed oil: soyabean oil = 2:1:1 (Ueda Oils and Fats), and test oils containing AA at 0·, 8·3, 58·3 and 400·0 mg/ml were prepared. Deficiency of n-3 PUFA was avoided by using CE-2 as the basal diet, as CE-2 contains a sufficient quantity of n-3 PUFA.

A total of sixty rats were randomly divided into six groups of ten rats each based on body weight. Four groups were given 0·6 ml/kg of vehicle oil or AA-rich oil mixtures, yielding dosages of AA at 0, 5, 35 and 240 mg/kg. The oils were administered once daily by gavage for 8 weeks. Dose levels were determined based on previous studies in humans(5,15); the lowest dose, 5 mg/kg per d, was comparable with the dose, 240 mg/kg per d, in those studies. The highest dose in the present study was approximately fifty times the lowest one— that is, about fifty times as high as that in a previous human study(15). The drinking water was replaced with water containing 3 % DSS (Wako Pure Chemical Industries) for the last 7 d in the 8th week of the AA administration period (i.e. the 0 and 240 mg/kg AA with DSS groups)(11,12). The other two groups were given 0·6 ml/kg of vehicle oil or AA-rich oil mixtures, yielding dosages of AA at 0 and 240 mg/kg per d without DSS treatment (i.e. the 0 and 240 mg/kg AA without DSS groups).

The protocol for the present study was approved by the Committee for Ethical Usage of Experimental Animals at Hatano Research Institute, Food and Drug Safety Center (authorisation no. 2100030A).

Gross observation, body weight, food intake and water intake

The general condition of the animals was observed daily. Faecal properties were classified into the following five categories: normal, loose, reddish brown-stained, red-stained and diarrhoea. Body weight and food intake were measured once a week. Daily water intake was measured for the last 7 d.

Haematological observation

After the 8-week AA administration period, the animals were fasted for 18 h. Under anaesthesia with pentobarbital, blood was collected from the abdominal vein using EDTA-2K as an anticoagulant. Densities of erythrocytes, leucocytes and platelets were measured; Hb, mean corpuscular volume (MCV), mean corpuscular haemoglobin and mean corpuscular haemoglobin concentration (MCHC) were determined; and differential leucocyte count, reticulocyte ratio and haematocrit (HCT) were calculated using an automated haematology analyser (XT-2000iV; Sysmex).

Biochemical analysis in plasma

Plasma was obtained from the blood samples taken from the abdominal vein using heparin as an anticoagulant, and the following parameters were determined using an auto-analyser (JCA-BM6010; JEOL): the concentrations of total protein, albumin, glucose, total cholesterol, TAG, phospholipids, NEFA, total bilirubin, blood urea nitrogen, creatinine, calcium ions and inorganic phosphorus; the albumin:globulin ratio; and the activities of γ-glutamyl transpeptidase, alkaline phosphatase, aspartate aminotransferase and alanine aminotransferase. The concentrations of sodium, potassium and chloride ions were measured using an electrolyte auto-analyser (EA05; A&T).

Measurement of plasma fatty acids

Plasma lipids were extracted using a chloroform/methanol mixture according to the method of Bligh et al.(16). Heptadecanoic acid (10 μl; Sigma) was added as an internal standard. Fatty acids yielded in the extract were heated and esterified in methanol containing 5 % HCl at 100°C for 1 h (Tokyo Kasei). Subsequently, fatty acid composition was determined by capillary column (0·25 mm diameter, 30 m length; J&W DB-225; Agilent Technologies) GLC (GC-18A; Shimadzu). The column temperature was held at 120°C for 2 min, then ramped up to 200°C at a rate of 5°C/min, then to 208°C at a rate of 3°C/min and held at 208°C for 45 min. The injector and detector temperatures were both set at 250°C.
**Pathological examination**

Following the collection of blood samples, the animals were killed by exsanguination and were necropsied.

The length and weight of the colon isolated from each animal were measured, and relative weight to length was calculated. Four pieces of the large intestine were cut in the following order, starting from the end closest to the anus, with the following lengths: approximately 3, 1, 4 and 1 cm. The second section was used for pathological examination, and the first and the third sections were used for eicosanoid analysis and ulcerated area measurement, respectively. The fourth section was used for measuring myeloperoxidase (MPO) activity and cyclo-oxygenase-2 (COX-2) concentration. The third section of the colon was opened along the long axis and placed in 3% acetic acid solution for 5 min. After being rinsed in water, the colon was stained with 1% Aecian blue solution for 20 min, followed by immersion in 3% acetic acid solution. Subsequently, the tissues were photographed (COOLPIX5700; Nikon). The total area of the areas stained dark blue in the mucosa were measured with Image J Software (Version 1.44p; NIH), and the ratio of stained areas to that of the colonic mucosa observed was calculated.

For evaluating macrophage infiltration, the sections of the caecum and colon in the 0 and 240 mg/kg AA with DSS groups were de-paraffinised and incubated with a primary antibody to CD68 (1:500; ABD) at 4°C overnight and, subsequently, with a secondary antibody (Simplestain MAX-PO; Nichirei Biosciences) for 20 min at room temperature. These preparations were stained with 1% Alcian blue solution for 20 min, followed by immersion in 3% acetic acid solution. Subsequently, the tissues were photographed (COOLPIX5700; Nikon). The total area of the areas stained dark blue in the mucosa were measured with Image J Software (Version 1.44p; NIH), and the ratio of stained areas to that of the colonic mucosa observed was calculated.

For evaluating macrophage infiltration, the sections of the caecum and colon in the 0 and 240 mg/kg AA with DSS groups were de-paraffinised and incubated with a primary antibody to CD68 (1:500; ABD) at 4°C overnight and, subsequently, with a secondary antibody (Simplestain MAX-PO; Nichirei Biosciences) for 20 min at room temperature. These preparations were stained with 3,3-diaminobenzidene (DAB; Dojindo Laboratories), and DAB-positive cells in five randomly selected microscopic fields were counted to calculate the density of DAB-positive cells.

The brain, heart, liver, kidneys, spleen, adrenals and testes were weighed, and the relative organ-to-body weights were calculated for individual animals. These organs, as well as the brain, were homogenised in a lysis buffer (IBLysis-1; Immuno-Biological Laboratories). The homogenates were maintained at 4°C for 10 min to centrifuge at 8000 g for 10 min at 4°C and the supernatants were obtained. COX-2 levels in the supernatants were assayed using a commercial ELISA kit (Rat COX-2 assay kit; Immunoo-Biological Laboratories) following the manufacturer's instructions. COX-2 levels were expressed as ng/mg protein. Protein concentrations in the sample homogenates were determined using a protein assay kit (BCA protein assay kit; Takara).

**Determination of eicosanoid concentrations in culture media of the colonic mucosa**

Isolated colonic mucosa, approximately 30 mg from each animal, was incubated in RPMI1640 medium containing 10% fetal bovine serum, 2 mU l-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (Life Technologies) for 24 h at 37°C in 5% CO2. After incubation, culture media was collected and stored at ~80°C until use. Thromboxane B2 (TXB2), 6-keto prostaglandin F1a (6-keto PGF1α), prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) were determined using commercially available EIA kits (Cayman Chemical). Concentrations of these eicosanoids were expressed as pg/mg protein. Protein concentrations in the samples were determined using a protein assay kit (BCA protein assay reagent kit; Takara).

**Statistical analysis**

The results of this study are presented as the mean values and their standard errors. Equality of variance was tested with Bartlett’s test, and differences between group mean values were evaluated by Dunnett’s test. When variance of values obtained was not equal, Kruskal–Wallis one-way ANOVA by ranks was used followed by Dunn’s test. A two-tailed unpaired t test was used when two group mean values were compared between 0 mg/kg AA with and without DSS groups, 0 and 240 mg/kg AA without DSS groups, and 0 and 240 mg/kg AA with DSS groups. Graded data in the pathological examinations were evaluated by Mann–Whitney’s U test. Dose-dependency was confirmed by regression analysis. Differences were considered statistically significant when the P value was <0.05.

**Results**

**Fatty acid composition of arachidonic acid-rich dietary oil and vehicle oil**

Results are shown in Table 1. AA content in AA-rich dietary oil and the vehicle oil were approximately 40-4 and 0-05 % (w/w), respectively.

**General condition, body weight and food and water intake**

At the end of the 8th week, anaemia was observed in animals in the DSS-treated groups: six, nine, six and nine animals in the 0, 5, 35 and 240 mg/kg AA with DSS groups, respectively. The incidence of anaemia was not different between the groups. On the 3rd day, and after, during the DSS treatment period, loose stools, diarrhoea and red-stained faeces were observed in each group (online Supplementary Table S1). Although the onset of these symptoms tended to be earlier in the 240 mg/kg AA group...
than in the other groups, the grades of symptoms were not different between the groups. In the groups without DSS treatment, there were no abnormal findings in any of the animals for 8 weeks.

Up to the 7th week of AA administration, body weight increased in all the animals, and there were no significant differences between the groups. In each group treated with DSS, the mean body weight at the last day of observation (day 56) tended to be lower than that on day 50. However, in the groups without DSS treatment, body weight increased until the last day of the AA administration period (data not shown). During the AA administration period, food intakes in all the groups tested were similar. Daily intake of the 3% DSS solution was not different of the AA administration period (data not shown).

Haematology and blood biochemistry

The results are shown in Table 2. In the differential leucocyte counts, neutrophils were decreased and lymphocytes were increased in the 240 mg/kg AA with DSS group compared with the 0 mg/kg AA with DSS group (P < 0.05). Reticulocytes in the 0 mg/kg AA with DSS group were higher than in the 0 mg/kg AA without DSS group (P < 0.001). Leucocyte count and MCV were increased in the 0 mg/kg AA with DSS group compared with the 0 mg/kg AA without DSS group (P < 0.001).

There were no significant differences in the blood biochemistry between the four groups treated with DSS (Table 3). In the 0 mg/kg AA with DSS group, the total protein, albumin and glucose levels as well as the albumin:globulin ratio were lower, and the total cholesterol, blood urea nitrogen and potassium levels were higher, compared with the 0 mg/kg AA without DSS group.

**Plasma fatty acids**

In the DSS-treated groups, plasma AA levels in the 240 mg/kg AA group were higher compared with the 0 mg/kg AA group. EPA:AA and (EPA + DHA):AA ratios between the DSS-treated groups were not different. The EPA:AA ratio in the 240 mg/kg AA group tended to be lower than that in the 0 mg/kg AA group (Fig. 1). In the groups without DSS treatment, AA level was higher, and EPA:AA and (EPA + DHA):AA ratios were lower in the 240 mg/kg AA group, compared with the 0 mg/kg AA group. The EPA:AA ratio in the 0 mg/kg AA without DSS group was higher compared with the 0 mg/kg AA with DSS group.

**Organ weights and macroscopic findings**

There were no differences in relative organ weights between the six groups (data not shown).

---

**Table 1. Fatty acid compositions of arachidonic acid (AA)-rich dietary oil and vehicle oil (% total fatty acids)**

(Mean values with their standard errors; n = 3)

<table>
<thead>
<tr>
<th>Fatty acid</th>
<th>0 mg/kg AA with DSS</th>
<th>0 mg/kg AA without DSS</th>
<th>240 mg/kg AA with DSS</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 : 0</td>
<td>0.40 ± 0.01</td>
<td>0.06 ± 0.01</td>
<td>0.07 ± 0.01</td>
</tr>
<tr>
<td>14 : 0</td>
<td>6.95 ± 0.01</td>
<td>0.91 ± 0.03</td>
<td>1.12 ± 0.02</td>
</tr>
<tr>
<td>18 : 0</td>
<td>5.91 ± 0.02</td>
<td>8.74 ± 0.01</td>
<td>8.41 ± 0.01</td>
</tr>
<tr>
<td>20 : 0</td>
<td>0.81 ± 0.004</td>
<td>0.34 ± 0.01</td>
<td>0.34 ± 0.01</td>
</tr>
<tr>
<td>22 : 0</td>
<td>3.21 ± 0.01</td>
<td>0.22 ± 0.003</td>
<td>ND</td>
</tr>
<tr>
<td>23 : 0</td>
<td>0.10 ± 0.01</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>24 : 0</td>
<td>9.51 ± 0.01</td>
<td>0.09 ± 0.01</td>
<td>ND</td>
</tr>
<tr>
<td>14 : 1</td>
<td>ND</td>
<td>0.14 ± 0.001</td>
<td>ND</td>
</tr>
<tr>
<td>16 : 1n-7</td>
<td>0.22 ± 0.001</td>
<td>1.35 ± 0.01</td>
<td>0.74 ± 0.04</td>
</tr>
<tr>
<td>18 : 1n-9</td>
<td>0.27 ± 0.004</td>
<td>2.54 ± 0.01</td>
<td>2.54 ± 0.01</td>
</tr>
<tr>
<td>20 : 1n-9</td>
<td>0.07 ± 0.01</td>
<td>0.79 ± 0.04</td>
<td>0.79 ± 0.04</td>
</tr>
<tr>
<td>22 : 1n-9</td>
<td>0.37 ± 0.01</td>
<td>22.26 ± 0.03</td>
<td>ND</td>
</tr>
<tr>
<td>24 : 1</td>
<td>0.38 ± 0.01</td>
<td>22.26 ± 0.03</td>
<td>ND</td>
</tr>
<tr>
<td>18 : 2n-6</td>
<td>2.40 ± 0.004</td>
<td>0.03 ± 0.01</td>
<td>ND</td>
</tr>
<tr>
<td>20 : 2n-6</td>
<td>0.47 ± 0.002</td>
<td>0.20 ± 0.01</td>
<td>ND</td>
</tr>
<tr>
<td>20 : 3n-6</td>
<td>3.85 ± 0.01</td>
<td>0.05 ± 0.002</td>
<td>ND</td>
</tr>
<tr>
<td>20 : 4n-6</td>
<td>45.11 ± 0.04</td>
<td>3.84 ± 0.01</td>
<td>ND</td>
</tr>
<tr>
<td>22 : 4n-6</td>
<td>0.31 ± 0.004</td>
<td>0.10 ± 0.001</td>
<td>ND</td>
</tr>
<tr>
<td>18 : 3n-3</td>
<td>0.06 ± 0.003</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>20 : 5n-3</td>
<td>0.52 ± 0.002</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>22 : 6n-3</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
</tbody>
</table>

ND, not detected.

---

**Note:**

(All values are presented as mean ± SD.)
Table 2. Haematology in the rats orally administered arachidonic acid (AA) for 8 weeks (Mean values with their standard errors; ten animals)

<table>
<thead>
<tr>
<th>Group</th>
<th>Erythrocytes (×10^4/µl)</th>
<th>HCT (%)</th>
<th>Hb (g/l)</th>
<th>RET (%)</th>
<th>MCV (fl)</th>
<th>MCH (pg)</th>
<th>MCHC (g/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SE</td>
<td>Mean</td>
<td>SE</td>
<td>Mean</td>
<td>SE</td>
<td>Mean</td>
</tr>
<tr>
<td>0 mg/kg AA with DSS</td>
<td>476·7****</td>
<td>63·5</td>
<td>26·3****</td>
<td>2·7</td>
<td>81****</td>
<td>1</td>
<td>16·9****</td>
</tr>
<tr>
<td>5 mg/kg AA with DSS</td>
<td>317·9</td>
<td>24·4</td>
<td>30·6</td>
<td>0·9</td>
<td>46·5**</td>
<td>4</td>
<td>10·5**</td>
</tr>
<tr>
<td>35 mg/kg AA with DSS</td>
<td>486·2</td>
<td>70·7</td>
<td>17·6</td>
<td>2·8</td>
<td>15·2</td>
<td>11</td>
<td>5·5**</td>
</tr>
<tr>
<td>240 mg/kg AA with DSS</td>
<td>362·3</td>
<td>61·4</td>
<td>15·1</td>
<td>1·8</td>
<td>11·5</td>
<td>10</td>
<td>6·0*</td>
</tr>
<tr>
<td>0 mg/kg AA without DSS</td>
<td>936·7</td>
<td>10·1</td>
<td>17·6</td>
<td>0·2</td>
<td>15·1</td>
<td>2</td>
<td>5·5**</td>
</tr>
<tr>
<td>240 mg/kg AA without DSS</td>
<td>912·4</td>
<td>11·1</td>
<td>15·6</td>
<td>0·5</td>
<td>11·2</td>
<td>2</td>
<td>5·5**</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Group</th>
<th>Leucocytes (×10^2/µl)</th>
<th>NEUT (%)</th>
<th>LYMPH (%)</th>
<th>MONO (%)</th>
<th>EOS (%)</th>
<th>BASO (%)</th>
<th>PLT (×10^4/µl)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SE</td>
<td>Mean</td>
<td>SE</td>
<td>Mean</td>
<td>SE</td>
<td>Mean</td>
</tr>
<tr>
<td>0 mg/kg AA with DSS</td>
<td>122·1****</td>
<td>7·6</td>
<td>21·3</td>
<td>1·6</td>
<td>12·4</td>
<td>0·2</td>
<td>8·3**</td>
</tr>
<tr>
<td>5 mg/kg AA with DSS</td>
<td>143·9</td>
<td>9·1</td>
<td>17·0</td>
<td>1·9</td>
<td>12·7</td>
<td>0·4</td>
<td>8·2**</td>
</tr>
<tr>
<td>35 mg/kg AA with DSS</td>
<td>147·7</td>
<td>10·0</td>
<td>20·2</td>
<td>1·7</td>
<td>13·9</td>
<td>0·3</td>
<td>8·2**</td>
</tr>
<tr>
<td>240 mg/kg AA with DSS</td>
<td>124·3</td>
<td>12·4</td>
<td>14·6†</td>
<td>1·3</td>
<td>12·8†</td>
<td>0·3</td>
<td>8·2**</td>
</tr>
<tr>
<td>0 mg/kg AA without DSS</td>
<td>61·9</td>
<td>3·9</td>
<td>21·4</td>
<td>1·2</td>
<td>11·5</td>
<td>0·1</td>
<td>7·6**</td>
</tr>
<tr>
<td>240 mg/kg AA without DSS</td>
<td>58·8</td>
<td>2·7</td>
<td>20·6</td>
<td>1·5</td>
<td>11·5</td>
<td>0·1</td>
<td>7·6**</td>
</tr>
</tbody>
</table>

HCT, haematocrit; RET, reticulocytes; MCV, mean corpuscular volume; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; DSS, dextran sodium sulphate; NEUT, neutrophils; LYMPh, lymphocytes; MONO, monocytes; EOS, eosinophils; BASO, basophils; PLT, platelets.

Mean value was significantly different from that of the 0 mg/kg AA without DSS group (unpaired t test): * P = 0·024, ** P = 0·018, *** P = 0·0003, **** P < 0·0001. † Mean value was significantly different from that of the 0 mg/kg AA with DSS group (P < 0·05; Dunnett’s test).
Table 3. Blood biochemistry of the rats orally administered arachidonic acid (AA) for 8 weeks (Mean values with their standard errors; ten animals)

<table>
<thead>
<tr>
<th>Group</th>
<th>TP (g/l)</th>
<th>ALB (g/l)</th>
<th>A/G</th>
<th>Glu (mmol/l)</th>
<th>TC (mmol/l)</th>
<th>TAG (mmol/l)</th>
<th>PL (mg/l)</th>
<th>NEFA (mEq/l)</th>
<th>tBil (μmol/l)</th>
<th>BUN (mg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 mg/kg AA with DSS</td>
<td>50**** 1</td>
<td>33**** 1</td>
<td>1.95** 0.08</td>
<td>7.4**** 0.3</td>
<td>61* 2</td>
<td>20 6</td>
<td>1080 70</td>
<td>0.88 0.17</td>
<td>0.51 0.00</td>
<td>240***** 20</td>
</tr>
<tr>
<td>5 mg/kg AA with DSS</td>
<td>49 1</td>
<td>32 1</td>
<td>1.83 0.06</td>
<td>7.5 0.2</td>
<td>57 4</td>
<td>30 6</td>
<td>1130 90</td>
<td>1.02 0.11</td>
<td>0.51 0.00</td>
<td>250 10</td>
</tr>
<tr>
<td>35 mg/kg AA with DSS</td>
<td>51 1</td>
<td>34 1</td>
<td>2.01 0.05</td>
<td>7.3 0.3</td>
<td>55 2</td>
<td>29 13</td>
<td>1050 70</td>
<td>0.88 0.15</td>
<td>0.51 0.00</td>
<td>230 10</td>
</tr>
<tr>
<td>240 mg/kg AA with DSS</td>
<td>50 1</td>
<td>32 1</td>
<td>1.76 0.06</td>
<td>7.7 0.2</td>
<td>59 2</td>
<td>24 5</td>
<td>1090 40</td>
<td>1.01 0.11</td>
<td>0.34 0.00</td>
<td>230 10</td>
</tr>
<tr>
<td>0 mg/kg AA without DSS</td>
<td>57 1</td>
<td>39 0</td>
<td>2.17 0.06</td>
<td>8.5 0.2</td>
<td>51 3</td>
<td>49 3</td>
<td>950 30</td>
<td>0.56 0.03</td>
<td>0.51 0.00</td>
<td>180 10</td>
</tr>
<tr>
<td>240 mg/kg AA without DSS</td>
<td>55 1</td>
<td>38 0</td>
<td>2.24 0.05</td>
<td>8.7 0.4</td>
<td>55 2</td>
<td>47 4</td>
<td>940 20</td>
<td>0.43 0.06</td>
<td>0.51 0.00</td>
<td>190 10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Group</th>
<th>Cre (μmol/l)</th>
<th>IP (mg/l)</th>
<th>ALP (U/l)</th>
<th>AST (U/l)</th>
<th>ALT (U/l)</th>
<th>γ-GTP (U/l)</th>
<th>Ca (mg/l)</th>
<th>Na (mEq/l)</th>
<th>K (mEq/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 mg/kg AA with DSS</td>
<td>44·2 0·0</td>
<td>66 2</td>
<td>444 21</td>
<td>71 8</td>
<td>48 5</td>
<td>1 0</td>
<td>94 1</td>
<td>141·9 0·5</td>
<td>5·22*** 0·51</td>
</tr>
<tr>
<td>5 mg/kg AA with DSS</td>
<td>44·2 0·0</td>
<td>64 2</td>
<td>481 31</td>
<td>68 7</td>
<td>56 8</td>
<td>2 1</td>
<td>93 1</td>
<td>141·5 0·3</td>
<td>5·62 0·36</td>
</tr>
<tr>
<td>35 mg/kg AA with DSS</td>
<td>44·2 0·0</td>
<td>65 2</td>
<td>487 24</td>
<td>82 16</td>
<td>67 19</td>
<td>1 1</td>
<td>94 1</td>
<td>141·5 0·5</td>
<td>4·98 0·44</td>
</tr>
<tr>
<td>240 mg/kg AA with DSS</td>
<td>53·0 0·0</td>
<td>64 2</td>
<td>453 20</td>
<td>60 5</td>
<td>47 7</td>
<td>1 0</td>
<td>94 1</td>
<td>141·4 0·3</td>
<td>5·20 0·36</td>
</tr>
<tr>
<td>0 mg/kg AA without DSS</td>
<td>44·2 0·0</td>
<td>66 1</td>
<td>464 11</td>
<td>65 1</td>
<td>43 2</td>
<td>0 0</td>
<td>95 1</td>
<td>142·5 0·1</td>
<td>3·78 0·15</td>
</tr>
<tr>
<td>240 mg/kg AA without DSS</td>
<td>44·2 0·0</td>
<td>66 2</td>
<td>483 19</td>
<td>69 3</td>
<td>41 2</td>
<td>0 0</td>
<td>93 1</td>
<td>142·8 0·3</td>
<td>3·64 0·08</td>
</tr>
</tbody>
</table>

TP, total protein; ALB, albumin; A/G, albumin:globulin ratio; Glu, glucose; TC, total cholesterol; PL, phospholipids; tBil, total bilirubin; BUN, blood urea nitrogen; DSS, dextran sodium sulphate; Cre, creatinine; IP, inorganic phosphate; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyltransferase; Ca, calcium ion; Na, sodium ion; K, potassium ion; Cl, chloride ion.

Mean value was significantly different from that of the 0 mg/kg AA without DSS group: * P = 0.028, ** P = 0.016, *** P = 0.015, **** P = 0.010, ***** P = 0.003, ***** P < 0.0001, (unpaired t test).
In each group with DSS treatment, a pale liver (five to eight animals per group) and an enlarged spleen (three to seven animals per group) were observed, although the incidence of these findings did not differ between the groups. In addition, a dark reddish caecum was observed in the 0, 5, 35 and 240 mg/kg AA groups (one, seven, two and six animals, respectively). In the groups without DSS treatment, there were no abnormal findings.

**Colon weights**

Mean relative colon weights in the 0, 5, 35 and 240 mg/kg AA with DSS groups were similar: 123.1 (SE 5.8), 118.0 (SE 7.6), 124.9 (SE 6.7) and 123.2 (SE 4.3) mg/cm, respectively. The relative colon weight in the 0 mg/kg AA with DSS group, 91.1 (SE 3.5) mg/cm ($P = 0.0002$), was significantly higher compared with the 0 mg/kg AA without DSS group and was comparable with that of the 240 mg/kg AA without DSS group − 92.6 (SE 2.7) mg/cm.

**Microscopic findings**

Hepatic extramedullary haematopoiesis was observed in the groups with DSS treatment, although the incidence was similar in all the groups. Haemorrhage in the submucosal tissues and erosion or ulceration in the epithelium were also observed in the colons of all the animals treated with DSS, and the grade and incidence were similar. Oedema in the colonic submucosa occurred more often in the 240 mg/kg AA with DSS group than in the 0 mg/kg AA with DSS group ($P < 0.05$). The numbers of oedema-positive animals were seven and four, respectively. Infiltration of inflammatory cells in the colonic and caecal tissues of the 240 mg/kg AA with DSS group appeared more marked compared with the 0 mg/kg AA with DSS group. There were no inflammatory findings in the organs including the colonic and caecal tissues in either the 0 or 240 mg/kg AA without DSS groups.

**CD68-positive cells in the colonic mucosa**

As abnormal findings in the caecum and colon were observed only in the 240 mg/kg AA with DSS group, immunohistochemical staining for CD68-positive cells was performed in the 0 and 240 mg/kg AA with DSS groups. In the caecum, CD68-positive cells were increased in the 240 mg/kg AA with DSS group (Fig. 2(a) and (c), $P = 0.008$). In the colon, although CD68-positive cells tended to be higher in the 240 mg/kg AA with DSS group (893 (SE 110) cells/mm² mucous membrane) compared with the 0 mg/kg AA with DSS group (730 (SE 75) cells/mm² mucous membrane), this difference was NS (Fig. 2(b) and (d)).

**Ulcerated area**

The Alcian blue-stained areas of the mucosa in the 0, 5, 35 and 240 mg/kg AA with DSS groups were 0.82 (SE 0.27), 1.24 (SE 0.14), 1.42 (SE 0.42) and 1.62 (SE 0.52)%, respectively (Fig. 3). These areas were found to be increased compared with those in the 0 and 240 mg/kg AA without DSS groups, 0.41 (SE 0.11) and 0.20 (SE 0.03)% respectively. There were no significant differences within the groups treated with DSS or within the groups without DSS treatment.

**Myeloperoxidase activity in colon tissue**

In the DSS-treated groups, AA intake dose-dependently increased MPO activity in the colonic tissues ($r^2 = 0.9999$). MPO activity in the 240 mg/kg AA group, 4.10 (SE 0.2)-mU/mg protein, was significantly higher than that in the 0 mg/kg AA group, 2.70 (SE 0.3)-mU/mg protein ($P < 0.01$, Fig. 4). The activities in the 0 and 240 mg/kg AA without DSS groups were low (0.54 (SE 0.2) and 0.92 (SE 0.2)-mU/mg protein, respectively). The activity in the 0 mg/kg AA with DSS group was higher compared with the 0 mg/kg AA without DSS group ($P < 0.0001$).

---

**Fig. 1.** Plasma arachidonic acid (AA) concentration and EPA:AA and (EPA+DHA):AA ratios in rats given AA for 8 weeks with and without dextran sodium sulphate (DSS) treatment. (a) AA concentration, (b) EPA:AA ratio, (c) (EPA+DHA):AA ratio. Values are means, with their standard errors represented by vertical bars. *Mean value was significantly different from the values in the 0 mg/kg AA with DSS group ($P < 0.05$; Dunnett’s test). $P = 0.0069$ (a), $P < 0.0001$ (b and c), significantly different from the values in the 0 mg/kg AA without DSS group (unpaired t-test). DSS+, with DSS treatment; DSS−, without DSS treatment.
Cyclo-oxygenase-2 in homogenised colon tissue

In the DSS-treated groups, COX-2 levels in the colonic tissues were increased by AA in a dose-dependent manner ($r^2 = 0.9407$). The COX-2 concentration in the 240 mg/kg AA group, $0.67 (SE 0.03)$ ng/mg protein, was higher compared with the 0 mg/kg AA group, $0.42 (SE 0.03)$ ng/mg protein ($P < 0.05$, Fig. 5). COX-2 level in the 0 mg/kg AA with DSS group was higher compared with the 0 mg/kg AA without DSS group, $0.05 (SE 0.02)$ ng/mg protein ($P < 0.0001$). There were no differences in concentrations between the groups without DSS treatment.

Eicosanoids in the culture media of the colonic mucosa

In the DSS-treated groups, the concentration of TXB$_2$ was dose-dependently increased by AA ($r^2 = 0.9990$) and was significantly higher in the 35 and 240 mg/kg AA groups than in the 0 mg/kg AA group ($P < 0.05$ and 0.01, respectively, Fig. 6(a)). The concentrations of 6-keto PGF$_{1\alpha}$ in the 5 and 240 mg/kg AA groups were lower compared with the 0 mg/kg AA group ($P < 0.05$, Fig. 6(b)). The concentrations of PGE$_2$ in the 5, 35 and 240 mg/kg AA groups tended to be higher compared with the 0 mg/kg AA group (Fig. 6(c)). The concentrations of LTB$_4$ in the 5, 35 and 240 mg/kg AA groups were higher compared with the 0 mg/kg AA group ($P < 0.05$ or 0.01, Fig. 6(d)), although the increase was not dose-dependent. The concentrations of 6-keto PGF$_{1\alpha}$ and PGE$_2$ in the 0 mg/kg AA with DSS group were higher compared with the 0 mg/kg AA without DSS group ($P = 0.0003$ and 0.0038, respectively), whereas TXB$_2$ and LTB$_4$ concentrations were not different. There were no significant differences in the concentrations of these four eicosanoids between the 0 and the 240 mg/kg AA without DSS groups.
Discussion

In the present study, red-stained faeces, body weight loss and decreases in erythrocytes, HCT and Hb were observed only in the DSS-treated groups. Increased MPO activity, which was reported in rats with DSS-induced colitis,[17] was also found in the DSS-treated animals. Thus, it was confirmed that the DSS treatment adopted in the present study effectively caused colitis. However, there were no significant changes by AA in the DSS-induced decrease in body weight or increase in relative colon weight. In these animals, the grades of loose stools, diarrhoea and red-stained faeces were also comparable. However, MPO and COX-2 in the colitic tissue and TXB2, 6-keto PGF1α and PGE2 in the cultured mucosa were found to be increased by AA administration. Moreover, macrophage infiltration in the colonic mucosa was also confirmed in the 240 mg/kg AA with DSS group. Thus, AA is considered to have proinflammatory effects on DSS-induced colitis.

In the 240 mg/kg AA without DSS group, plasma levels of AA was significantly higher compared with the 0 mg/kg AA without DSS group, and EPA/AA and (EPA + DHA)/AA ratios were reduced to approximately 50 and 70% of those in the 0 mg/kg AA without DSS group, respectively. Such a reduction could be due to an increased level of plasma AA. In patients with ulcerative colitis, AA level was elevated in the colonic mucosa,[19] and high AA and low EPA levels were found in inflamed colonic mucosa.[19] In addition, the n-6 PUFA synthetic pathway was found to be up-regulated in colitis.[19] It has also been reported that patients with inflammatory bowel disease possibly utilised more AA than healthy subjects because the AA ratio in plasma NEFA was lower in those patients.[20] As a decreased EPA/AA ratio is one of the indicators for inflammatory diseases, the relatively lower EPA/AA ratio in the 240 mg/kg AA with DSS group may be an unfavourable condition, at least for the prevention of inflammatory diseases.

PGE2 and 6-keto PGF1α concentrations in the culture media of colonic mucosa of the AA at 0 mg/kg per d with DSS treatment group were significantly increased compared with the AA at 0 mg/kg per d without DSS treatment group. However, neither TXB2 nor LTB4 concentrations changed in these animals. Thus, at least under the present experimental conditions, DSS treatment appears to affect the syntheses of specific eicosanoids.

In the DSS-treated groups, a dose-dependent increase by AA of TXB2 was found in the culture media of colonic mucosa from

Fig. 3. Ulcerated area in the colon of rats given arachidonic acid (AA) for 8 weeks with and without dextran sodium sulphate (DSS) treatment. Isolated colon (approximately 4 cm) was opened along its long axis and stained with 1% Alcian blue solution. The ratio of stained areas to unstained areas of the colonic mucosa was calculated. Values are means, with their standard errors represented by vertical bars. *Mean value was significantly different from the values in the 0 mg/kg AA without DSS group (P < 0.01; Dunnett’s test). †Significantly different from the values in the 0 mg/kg AA without DSS group (P < 0.0001; unpaired t test). DSS + , with DSS treatment; DSS −, without DSS treatment.

Fig. 4. Myeloperoxidase (MPO) activities in the colon of rats orally administered arachidonic acid (AA) for 8 weeks with and without dextran sodium sulphate (DSS) treatment. Values are means, with their standard errors represented by vertical bars. **Mean value was significantly different from the values in the 0 mg/kg AA with DSS group (P < 0.01; Dunnett’s test). ††Significantly different from the values in the 0 mg/kg AA without DSS group (P < 0.0001; unpaired t test). DSS + , with DSS treatment; DSS −, without DSS treatment.

Fig. 5. Cyclo-oxygenase-2 (COX-2) concentration in the colon of rats orally administered arachidonic acid (AA) for 8 weeks with and without dextran sodium sulphate (DSS) treatment. Values are means, with their standard errors represented by vertical bars. *Mean value was significantly different from the values in the 0 mg/kg AA with DSS group (P < 0.05; Dunnett’s test). ††Significantly different from the values in the 0 mg/kg AA without DSS group (P < 0.0001; unpaired t test). DSS + , with DSS treatment; DSS −, without DSS treatment.
the rats given AA at 0–240 mg/kg per d. The increase in TXB₂ was significant in the AA at 35 and 240 mg/kg per d groups compared with the AA at 0 mg/kg per d group. PGE₂ in the culture media tended to increase in the groups given AA at 5, 35 and 240 mg/kg per d compared with the AA at 0 mg/kg per d group. Furthermore, LTB₄ concentration in the AA at 5, 35 and 240 mg/kg per d groups was significantly higher compared with the AA at 0 mg/kg per d group, although this change was not dose-dependent. These results demonstrate that AA increases TXB₂, PGE₂ and LTB₄ concentrations in colitic mucosa of DSS-treated rats. The increases in these eicosanoids occurred at 5 mg/kg per d and appeared to be saturated, except for TXB₂, which showed a dose-dependent increase. However, 6-keto PGF₁α concentration in the culture media in the AA at 5 and 240 mg/kg per d groups was significantly lower compared with the AA at 0 mg/kg per d group. Although the reason for such a decrease is not clear, it should be noted that AA-induced changes in the levels of eicosanoids, including the decrease in 6-keto PGF₁α, led to the facilitation of an underlying inflammation, and the effects appear even at 5 mg/kg per d. In contrast, in the rats without DSS treatment, no significant differences in these four eicosanoids were observed between the AA at 0 and 240 groups, suggesting the lack of proinflammatory effects of AA in rats without an underlying inflammation.

Lipoxin A₄, resolvin E₁ and Maresin 1 are PUFA-derived mediators that have anti-inflammatory effects in experimental models of colitis. It has been shown in patients with inflammatory bowel disease and in mice with DSS-induced colitis that there is a relationship between PUFA and enterobacterial flora in the bowel, which is affected by inflammation. Thus, although not examined in the present study, investigations regarding the role of these mediators in inflammatory diseases and the influence of enterobacterial flora in relation to AA intake are necessary.

On macroscopic observation, a dark red colouration was observed in the colons of animals in the DSS-treated groups.

Fig. 6. Eicosanoids in culture media of the colonic mucosa of rats orally administered arachidonic acid (AA) for 8 weeks with and without dextran sodium sulphate (DSS) treatment. (a) Thromboxane B₂ (TXB₂), (b) 6-keto prostaglandin F₁α (6-keto PGF₁α), (c) prostaglandin E₂ (PGE₂), (d) leukotriene B₄ (LTB₄). Values are means, with their standard errors represented by vertical bars. Mean value was significantly different from that of the 0 mg/kg AA with DSS group: *P < 0.05, **P < 0.01 (Dunnett’s test). P = 0.0003 (b), P = 0.0038 (c), significantly different from the values in the 0 mg/kg AA without DSS group (unpaired t test). DSS +, with DSS treatment; and DSS –, without DSS treatment.
Although the effect was not dose-dependent, the DSS-induced mucosal oedema in the colon was aggravated by AA at 240 mg/kg and was accompanied by an increased local macrophage infiltration. This increase was significant in the caecum. As the expressions of IL-1β, IL-6, TNFα and IL-17 were reported in macrophages from patients with colitis\(^\text{\textsuperscript{25-28}}\), the involvement of such inflammatory cytokines in the exacerbation of DSS-induced colitis by AA in rats remains to be elucidated.

Both MPO activity and COX-2 concentration in the colonic tissue were markedly increased by DSS treatment and were facilitated by AA in a dose-dependent manner, suggesting an aggravation by AA of DSS-induced colitis. The Alcian blue-stained ulcerated area tended to be increased by AA, although this was not statistically significant. A higher dose of AA than 240 mg/kg per d may lead to further progression of ulceration or deterioration of the bowel disease in rats, as the tendency of the increase in the ulceration was dose-dependent and not saturated, even at 240 mg/kg per d. In addition, AA may change the differential leucocyte count, as the lymphocyte ratio, which increases in chronic inflammatory conditions, was elevated in the AA at 240 mg/kg with DSS-induced colitis group. However, MPO activity in the 240 mg/kg AA without DSS group was not different from that in the 0 mg/kg AA without DSS group. This finding demonstrates that AA does not induce inflammation or colitis in a normal colon.

In the present study, the groups of rats were configured not only for examining AA effects on DSS-induced colitis but also for a safety evaluation of AA. In the 240 mg/kg per d AA without DSS group, every parameter examined was comparable with that of the 0 mg/kg per d AA without DSS group, except for increased plasma AA level, indicating that AA at 240 mg/kg per d, roughly fifty times the dose in a previous study\(^\text{15}\), has no adverse effects in rats without DSS-induced colitis.

In summary, the 8-week repeated administration of AA at 5, 35 and 240 mg/kg per d had almost no effects in rats without DSS-induced colitis. However, in rats with DSS-induced colitis, AA at 240 mg/kg exacerbated the inflammation. Moreover, AA-induced increases in the production of PGE\(_2\) and LT\(_B_2\) and a decrease of PG\(_I_2\) were found in the culture media of colonic mucosa from rats with DSS-induced colitis, and these changes appeared saturated at 5 mg/kg per d.

Thus, it can be concluded that AA intake possibly enhances underlying inflammation and an excessive intake may aggravate inflammatory diseases, although AA appears to be safe for those in a healthy condition.

**Acknowledgements**

This work was supported in part by the Programme for the Health and Labour Sciences Research Grants, Japan (H22-food-general-002, H24-food-general-004), and the Grant-in-Aid for Scientific Research (C), Japan (24501030, 26550133).

The authors’ contributions are as follows: Y. N. designed the study; Y. N. and N. O. wrote the manuscript; Y. N., X. J., S. T., S. A. and N. I. performed the animal experiments and the data analyses; M. F. and Y. T. performed the biochemical and haematological examinations; D. M., A. H. and T. M. performed the analysis of fatty acids; and Y. N., X. J. and T. N. performed the pathological examinations. All the authors were responsible for the final manuscript.

The authors would like to thank Mr David L. Carleton for his help in correcting the English.

The authors declare no conflicts of interest.

**Supplementary Material**

For supplementary material/s referred to in this article, please visit http://dx.doi.org/10.1017/S000711451500224X.

**References**

2. McGahon B, Clements MP & Lynch MA (1997) The ability of aged rats to sustain long-term potentiation is restored when the age-related decrease in membrane arachidonic acid concentration is reversed. Neuroscience 81, 9–16.
acids and lipoxin A4 contents in colon, but does not affect severity or prostaglandin E2 content in murine colitis model. *Lipids Health Dis* 13, 30.


